Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology
Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make…
Dianthus
Follow these 7 tips when pipetting small volumes to get consistent assay results
If you’ve ever had to pipette really small volumes, such as what is required in…
6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the…
3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs
A caveat to a successful pharmaceutical industry in which many effective drugs have already been…
The NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper…
3 big takeaways from SLAS on the future of automation and screening
5,200 researchers, representing all of life sciences, gathered in San Diego in late January to…
When aptamers are the better choice over mAbs
Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is…
6 ingredients for a successful fragment library
Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in…
PROTACs: the game-changing technology that promises to tackle “undruggable” proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity.…